Osteoprotegerin Production by Breast Cancer Cells Is Suppressed by Dexamethasone and Confers Resistance Against TRAIL-induced Apoptosis
Osteoprotegerin Production by Breast Cancer Cells Is Suppressed by Dexamethasone and Confers Resistance Against TRAIL-induced Apoptosis
复制标题
DOI:
10.1002/jcb.22232
复制
发表时间:
2009-09-01
影响因子:
4
通讯作者:
Hofbauer, Lorenz C.
中科院分区:
文献类型:
--
作者:
Rachner, Tilman D.;Benad, Peggy;Hofbauer, Lorenz C.
Osteoprotegerin (OPG) is a decoy receptor for receptor activator of NF-kappa B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). While RANKL is essential for osteoclastogenesis and facilitates breast cancer migration into bone, TRAIL promotes breast cancer apoptosis. We analyzed the expression of OPG and TRAIL and its modulation in estrogen receptor-positive MCF-7 cells and receptor-negative MDA-MB-231 cells. In both cells, OPG mRNA levels and protein secretion were dose- and time-dependently enhanced by interleukin (IL)-1 beta and suppressed by dexamethasone. In contrast to MCF-7 cells, MDA-MB-231 abundantly expressed TRAIL mRNA, which was enhanced by IL-1 beta and inhibited by dexamethasone. TRAIL activated pro-apoptotic caspase-3, -7, and poly-ADP-ribose polymerase and decreased cell numbers of MDA-MB-231, but had no effect on MCF-7 cells. Gene silencing siRNA directed against OPG resulted in a 31% higher apoptotic rate compared to non-target siRNA-treated MDA-MB-231 cells. Furthermore, TRAIL induced significantly less apoptosis in cells cultured in conditioned media (containing OPG) compared to cells exposed to TRAIL in fresh medium lacking OPG (P